To test whether PI3Kδ inhibition enhanced the antitumor capacity of T cells similarly to direct AKT inhibition, CD8+ T cells from pmel-1 transgenic mice (CD8+ T cells with a transgenic TCR specific for the melanoma/melanocyte antigen gp100) were activated with their cognate antigen and treated with CAL-101 throughout culture. The gene discussed is AKT1; the disease is melanoma.